Immunotherapy, particularly immune checkpoint blockade, has transformed the oncology landscape by harnessing the immune system to recognize and eradicate tumors. However, therapeutic efficacy is often heterogeneous, influenced by tumor biology, host immunity, and extrinsic factors such as concomitant medications. Steroids and antibiotics, widely prescribed for symptom management and infection control in cancer patients, have been suspected to interfere with immunotherapy by altering immune responses or the gut microbiome, respectively. Yet, their precise impact and the significance of treatment timing remained elusive until now.

The pooled analysis by Wiest et al. meticulously evaluated over a thousand cancer patients enrolled across multiple tumor types, primarily focusing on urothelial carcinoma and renal cell carcinoma cohorts. By robustly stratifying patients according to their administration of steroids and antibiotics—differentiating between those who received these agents prior to or concurrently with immunotherapy—the investigators delineated distinct outcome patterns. Remarkably, prior use of steroids was correlated with a pronounced reduction in overall survival and progression-free survival, whereas steroids administered concomitantly exhibited a comparatively modest effect.

This temporal distinction underscores the critical window in which immune modulation by steroids can blunt the reinvigoration of T-cells induced by checkpoint inhibitors. Prednisone and related glucocorticoids, well-known for their potent immunosuppressive actions, may impair antigen presentation and T-cell activation when administered before immunotherapy initiation. Conversely, when given concomitantly under careful medical supervision, steroids might mitigate immune-related adverse events without profoundly diminishing anti-tumor efficacy.

Similarly, the impact of antibiotics on immunotherapy outcomes was dissected with granularity. The study reaffirms the growing evidence that prior antibiotic exposure, by disrupting gut microbiota diversity, detrimentally influences immune checkpoint blockade effectiveness. Specifically, patients receiving antibiotics within a month before immunotherapy manifest lower response rates and survival metrics. However, antibiotic use during the immunotherapy course showed a less detrimental impact, suggesting a complex interplay mediated partly by microbial recolonization dynamics.

The gut microbiome’s role in modulating systemic immunity and cancer therapy outcomes has emerged as a frontier in oncology research. Antibiotic-induced dysbiosis can impair antigen-presenting capacity, reduce effector T-cell priming, and hinder cytokine production critical for tumor rejection. These mechanistic insights align with the clinical correlations unearthed in this analysis, emphasizing the need for judicious antibiotic stewardship in oncology settings, particularly in the lead-up to immunotherapy.

Importantly, the pooled nature of this evidence adds statistical power and generalizability, overcoming limitations of single-cohort studies. By encompassing diverse immunotherapy regimens and cancer subtypes, the findings provide compelling real-world relevance. They suggest that oncologists must carefully contemplate the indication, timing, and necessity of steroids and antibiotics to optimize immunotherapy success.

Moreover, this study highlights the beneficial implications of integrated multidisciplinary management, where infectious disease specialists, oncologists, and immunologists collaborate to forge treatment pathways minimizing immune interference. Personalized approaches considering microbiome preservation and tailored immunosuppression may herald improved survival and quality of life for cancer patients receiving immune checkpoint blockade.

Future directions prompted by this work include prospective trials to examine microbiome restoration strategies, such as fecal microbiota transplantation or targeted probiotics, combined with immunotherapy. Furthermore, the potential development of biomarkers predicting corticosteroid and antibiotic susceptibility effects on treatment response could refine patient selection and management algorithms.

This research also raises caution about the widespread empirical use of steroids and antibiotics in oncology, underscoring the importance of evidence-driven protocols. While immunotherapy remains a cornerstone of modern cancer care, its full potential can only be realized by understanding and mitigating factors that compromise its efficacy. By illuminating the timing-sensitive effects of supportive medications, Wiest and colleagues deliver a vital message: not just which agents are administered, but precisely when they are given matters profoundly for therapeutic outcomes.

Clinicians should now consider avoiding unnecessary pre-treatment steroids and limiting antibiotic exposure before immunotherapy whenever clinically feasible. Simultaneously, in cases demanding steroid use for immune-related toxicities, vigilant dosing and timing optimization are imperative to balance benefits against potential dampening of anti-tumor immunity. This nuanced approach promises to elevate immunotherapy from a hopeful innovation to a reliably effective modality across broader patient populations.

In conclusion, this landmark pooled analysis from the German AIO Study Group presents compelling evidence that the timing of steroid and antibiotic administration distinctly influences immunotherapy efficacy in cancer. The delicate immunological landscape navigated by checkpoint inhibitors can be profoundly shaped by antecedent medication exposures, framing new therapeutic considerations for clinicians worldwide. As immunotherapy continues its ascent as a transformative cancer treatment, these findings chart a path toward more informed, precise, and effective integration of supportive care to maximize patient outcomes.

The clinical oncology community, patients, and researchers alike stand to benefit from this enhanced understanding of pharmacological interactions with immunotherapy’s complex mechanisms. The evolving narrative of cancer care increasingly emphasizes precision—not only in targeting tumors but also in tailoring supportive therapies that coexist harmoniously with immune activation. This study represents a pivotal step in that direction, promising to inform guidelines and catalyze innovations that ultimately save lives.

Subject of Research: The influence of prior versus concomitant steroid and antibiotic treatment on the efficacy of cancer immunotherapy.

Article Title: Differential effects of prior versus concomitant Steroid and Antibiotic Treatment on Immunotherapy Efficacy – A Pooled Analysis of the RAMONA, INTEGA, OPTIM, ELDORANDO, FORCE, TITAN-RCC and TITAN-TCC Trials of the German AIO Study Group.

Article References:
Wiest, I.C., Dreikhausen, L., Keller, R. et al. Differential effects of prior versus concomitant Steroid and Antibiotic Treatment on Immunotherapy Efficacy – A Pooled Analysis of the RAMONA, INTEGA, OPTIM, ELDORANDO, FORCE, TITAN-RCC and TITAN-TCC Trials of the German AIO Study Group. British Journal of Cancer (2026). https://doi.org/10.1038/s41416-026-03428-8

Image Credits: AI Generated

DOI: 19 May 2026

Peritoneal metastasis in gastric cancer notoriously portends a grim prognosis due to its association with high rates of treatment resistance and recurrence. Traditional chemotherapeutic regimens have proven inadequate, necessitating novel, combinatorial strategies that can potentiate tumor regression while minimizing adverse events. The integration of immune checkpoint inhibitors like PD-1 blockers with established chemotherapy and targeted antiangiogenic agents such as bevacizumab opens new therapeutic vistas by simultaneously attacking tumor cells and modulating the tumor microenvironment.

The clinical trial in question enlisted ten patients diagnosed with gastric cancer accompanied by peritoneal metastasis, subdividing them into two arms predicated on the severity of ascites—an often complicating feature in such patients. Patients manifesting moderate to large ascites were allocated to receive intraperitoneal delivery of bevacizumab alongside albumin-bound paclitaxel, S-1 oral chemotherapy, and the PD-1 targeting antibody sintilimab. Conversely, those with absent or minimal ascites were administered bevacizumab intravenously in combination with the same systemic agents.

This stratified therapeutic framework leverages the pharmacokinetic advantages inherent to intraperitoneal administration, ensuring heightened local drug concentrations within the peritoneal cavity, thereby maximizing direct tumoricidal effects on peritoneal implants and malignant ascitic cells. Intravenous administration, however, remains indispensable for systemic disease control and is preferred in patients with minimal peritoneal fluid accumulation.

Efficacy outcomes were rigorously evaluated through progression-free survival (PFS) and overall survival (OS) metrics, which revealed encouraging signals. The median PFS in the intraperitoneal arm was reported at 5.7 months, while the intravenous arm exhibited a longer median PFS of 9.07 months. Overall survival medians were observed at 8.43 months and 11.23 months for intraperitoneal and intravenous arms respectively, underscoring a trend toward enhanced survival benefits with systemic delivery in this limited cohort.

Safety profiles were also meticulously monitored, with Grade 3/4 adverse events occurring in 25% of patients receiving intraperitoneal bevacizumab and 16.7% in those receiving intravenous administration. These findings denote a manageable toxicity landscape, bolstering the feasibility of this combination regimen in a population notoriously vulnerable to treatment-related complications due to their advanced disease status.

At the molecular nexus, PD-1 inhibitors reinvigorate exhausted cytotoxic T-cells, restoring antitumor immunity often suppressed in the tumor microenvironment of advanced gastric cancer. Concurrently, bevacizumab, a monoclonal antibody targeting vascular endothelial growth factor (VEGF), impedes angiogenesis, thereby curtailing tumor nourishment and metastatic potential. This dual mechanistic attack, supported by cytotoxic chemotherapies, amplifies overall antineoplastic efficacy.

The albumin-bound paclitaxel component capitalizes on nanoparticle albumin-bound (nab) technology to enhance solubility and tumor penetration, while S-1, an oral fluoropyrimidine derivative, maintains continuous antitumor pressure through sustained biochemical modulation. The combination thus orchestrates a comprehensive cytotoxic and immunomodulatory onslaught, accentuated by locoregional targeting via intraperitoneal bevacizumab when indicated.

This study’s design as an open-label, two-arm pilot trial was pivotal in generating early clinical insights yet reflects limitations inherent to small sample sizes and lack of randomization. Nonetheless, its findings pave the way for larger, controlled trials which might definitively establish optimal administration routes and elucidate potential biomarkers predictive of response to this tripartite regimen.

Importantly, the trial was registered at the Chinese Clinical Trial Registry, underscoring a commitment to transparent, ethical research practices. This framework ensures that emerging data contributes meaningfully to the global scientific discourse on gastric cancer therapeutics.

Looking ahead, integrating immunotherapeutic regimens with traditional cytotoxic agents is increasingly recognized as a paradigm-shifting approach, especially in malignancies characterized by immunosuppressive niches and complex metastatic patterns such as gastric cancer with peritoneal dissemination. This study underscores the critical importance of personalized therapeutic strategies tailored not only to disease phenotype but also microenvironmental factors like ascitic burden.

The implications of this research extend beyond immediate clinical application; they beckon a deeper exploration into the interplay between chemotherapy, immunotherapy, and antiangiogenic strategies within the peritoneal tumor microenvironment. Understanding this crosstalk may identify novel targets and refine combination modalities further.

In summary, the investigational regimen of albumin-bound paclitaxel and S-1 chemotherapy, combined with PD-1 blockade and tailored bevacizumab administration, offers a beacon of hope for a patient subset long facing dismal prognosis. While preliminary, these encouraging results illuminate a path toward more efficacious, tolerable treatment paradigms for gastric cancer patients burdened by peritoneal metastasis.

Continued research efforts must validate and extend these findings, potentially integrating cutting-edge biomarkers and imaging modalities to monitor therapeutic responses dynamically. Such advances could ultimately translate into increased survival rates and improved quality of life for patients confronting this formidable disease.

This study exemplifies how convergent biomedical innovations—chemotherapy, immunotherapy, and targeted therapy—can be harmonized to tackle complex oncological challenges. As the oncology community stands on the cusp of transformative change, such pioneering clinical trials offer invaluable insights and hope.

Subject of Research: Safety and efficacy of combining systemic chemotherapy with PD-1 inhibitors and intravenous or intraperitoneal bevacizumab in treating gastric cancer with peritoneal metastasis.

Article Title: Safety and efficacy of systemic chemotherapy plus PD-1 inhibitor in combination with intravenous or intraperitoneal bevacizumab in gastric cancer with peritoneal metastasis.

Article References:
Ma, Y., Li, Y., Lin, Z. et al. Safety and efficacy of systemic chemotherapy plus PD-1 inhibitor in combination with intravenous or intraperitoneal bevacizumab in gastric cancer with peritoneal metastasis. BMC Cancer 25, 1010 (2025). https://doi.org/10.1186/s12885-025-14206-9

Image Credits: Scienmag.com

DOI: https://doi.org/10.1186/s12885-025-14206-9

Hepatocellular carcinoma, especially at advanced stages, remains a formidable challenge in oncology due to its high mortality rates and often limited therapeutic options. Lenvatinib, a tyrosine kinase inhibitor targeting angiogenesis pathways, has been widely used as a first-line treatment, but resistance or failure commonly develops, necessitating effective second-line interventions. Tislelizumab, a programmed death-1 (PD-1) inhibitor, has surfaced as a promising agent in this therapeutic niche, with prior evidence supporting its antitumor activity through immune checkpoint blockade.

The study retrospectively analyzed 51 patients diagnosed with Barcelona Clinic Liver Cancer (BCLC) stage C HCC who experienced disease progression after lenvatinib therapy. Patients were divided into two cohorts: those receiving a combination treatment of tislelizumab and lenvatinib (TL group) and those treated with tislelizumab monotherapy (T group). The primary endpoints evaluated were overall survival (OS) and progression-free survival (PFS), with secondary measures focusing on objective tumor responses and safety profiles.

Statistical analysis revealed a meaningful extension in PFS for the TL group, registering a median duration of 6.8 months versus 4.5 months observed in the T group, a difference bearing statistical significance (p=0.003). Similarly, OS was notably prolonged in the combination cohort, with patients surviving a median 14.0 months compared to 10.4 months among those on monotherapy (p=0.012). These findings underscore the potential synergistic effect of continuing lenvatinib alongside PD-1 blockade, even after initial lenvatinib resistance.

While the disease control rate was numerically superior in the TL cohort (64%) relative to monotherapy patients (53.8%), this difference did not achieve statistical significance (p=0.461). Likewise, the objective response rate favored the combination group (20% versus 7.7%), yet the p-value of 0.202 suggests more extensive studies are required to confirm definitive tumor shrinkage benefits. These nuances highlight the complex interplay between tumor biology and immune modulation, indicating the need for further biomarker-driven refinements.

An intriguing aspect of the study was the influence of liver function, assessed through the Child–Pugh classification, on therapy outcomes. Patients exhibiting better hepatic reserve (Child–Pugh A) derived a significant OS advantage from combination therapy, with median survival extending to 14.0 months compared to 12.0 months on monotherapy (p=0.013). Conversely, individuals with compromised hepatic function (Child–Pugh B) did not show statistically significant survival improvements, signaling the critical role of liver health in therapeutic efficacy and tolerability.

In exploring prognostic factors using Cox proportional hazards regression models, the researchers identified Child–Pugh B status and the choice of monotherapy as independent predictors of poor overall survival. Notably, for progression-free survival, only monotherapy was a negative prognostic factor, while impaired liver function did not exert a measurable impact. These findings suggest that immune-kinase inhibitor combination regimens may partially mitigate the deleterious consequences of hepatic insufficiency on disease progression, though survival remains vulnerable.

Safety profiles between the two groups displayed remarkable similarities, alleviating concerns over increased toxicity associated with combination treatment. The most frequently reported treatment-related adverse events (AEs) within the TL ensemble included hand–foot skin reactions (32%), hypertension (28%), diarrhea (32%), and hypothyroidism (20%). Approximately one in four patients experienced grade 3 or higher AEs, predominantly severe hand–foot reactions and diarrhea, yet these were manageable and did not dramatically affect adherence or quality of life.

The tolerability of the dual-agent approach is particularly promising given the delicate clinical balance in advanced HCC, where liver dysfunction often complicates the administration of aggressive therapies. The comparable AE incidence between groups reinforces the feasibility of employing tislelizumab plus lenvatinib as a second-line strategy, potentially reshaping clinical paradigms where monotherapy has traditionally prevailed after first-line failure.

Mechanistically, the continued use of lenvatinib alongside immune checkpoint inhibition may sustain antiangiogenic pressure on the tumor microenvironment, thereby enhancing immune cell infiltration and potentiating T-cell mediated cytotoxicity initiated by PD-1 blockade. This multifactorial mode of action aligns with emerging evidence supporting combined modality treatments to overcome immune resistance in hepatocellular carcinoma landscapes.

Moreover, the real-world nature of this analysis provides invaluable clarity on treatment effectiveness outside the rigid confines of controlled clinical trials, reflecting patient heterogeneity and the complexity of comorbidities typical in daily oncology practice. Although the retrospective design and single-center scope impose intrinsic limitations, the study’s robust statistical associations merit further prospective exploration and validation in diverse populations.

These findings hold significant clinical implications, advocating for a more nuanced approach to HCC management, integrating liver functional status alongside tumor biology to guide therapeutic decisions. For patients maintaining adequate hepatic reserves, the combination of tislelizumab and lenvatinib may offer a lifeline, extending survival and delaying progression with manageable side effects.

Future research should focus on elucidating biomarkers predictive of response to combination therapy to maximize patient selection precision. Additionally, trials investigating optimal dosing, scheduling, and potential integration with locoregional therapies could amplify the benefits observed and potentially transform standards of care in advanced liver cancer management.

In conclusion, the retrospective study compellingly demonstrates that in patients with advanced stage C hepatocellular carcinoma refractory to lenvatinib monotherapy, the addition of tislelizumab to lenvatinib confers significant survival benefits without compromising safety. The stratification by liver function highlights the necessity of personalized medicine in this domain and sets the stage for further innovations aiming to improve outcomes in this challenging patient population.

Subject of Research: Comparative efficacy and safety of tislelizumab plus lenvatinib versus tislelizumab monotherapy in advanced hepatocellular carcinoma after lenvatinib failure

Article Title: Comparative efficacy of tislelizumab plus lenvatinib and tislelizumab alone against advanced hepatocellular carcinoma after lenvatinib failure: a real-world study

Article References:
Yang, J., Xu, Q., Luo, S. et al. Comparative efficacy of tislelizumab plus lenvatinib and tislelizumab alone against advanced hepatocellular carcinoma after lenvatinib failure: a real-world study. BMC Cancer 25, 708 (2025). https://doi.org/10.1186/s12885-025-14092-1

Image Credits: Scienmag.com

DOI: https://doi.org/10.1186/s12885-025-14092-1